학술논문
Guselkumab for the treatment of moderate-to-severe plaque psoriasis.
Document Type
Academic Journal
Author
Yang EJ; a Department of Dermatology , University of California - San Francisco , San Francisco , CA , USA.; b Chicago Medical School , Rosalind Franklin University of Medicine and Science , North Chicago , IL , USA.; Sanchez IM; a Department of Dermatology , University of California - San Francisco , San Francisco , CA , USA.; c University of Illinois at Chicago College of Medicine , Chicago , IL , USA.; Beck K; a Department of Dermatology , University of California - San Francisco , San Francisco , CA , USA.; Sekhon S; a Department of Dermatology , University of California - San Francisco , San Francisco , CA , USA.; Wu JJ; d Department of Dermatology , Kaiser Permanente Los Angeles Medical Center , Los Angeles , CA , USA.; Bhutani T; a Department of Dermatology , University of California - San Francisco , San Francisco , CA , USA.
Source
Publisher: Taylor & Francis Country of Publication: England NLM ID: 101278296 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1751-2441 (Electronic) Linking ISSN: 17512433 NLM ISO Abbreviation: Expert Rev Clin Pharmacol Subsets: MEDLINE
Subject
Language
English
Abstract
Introduction: Guselkumab is a human monoclonal antibody targeting the p19 subunit of IL-23 that has been approved for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. This medication blocks the IL-23/IL-17 axis, which has been implicated in playing a key role in the pathogenesis of psoriasis. Areas covered: This review outlines the pharmacologic properties, safety, and efficacy of guselkumab for the treatment of plaque psoriasis. Expert commentary: Guselkumab is the first IL-23 specific inhibitor to be approved for the treatment of plaque psoriasis. Phase II and III clinical trial results have demonstrated excellent safety and efficacy of guselkumab. IL-23 inhibitors may offer potential benefits over existing therapies for moderate-to-severe plaque psoriasis in terms of safety, frequency of administration, and efficacy. Long-term safety data will be critical in evaluating the role of guselkumab in the treatment of psoriasis.